Aspirin seems as effective as myelosuppressive agents in the prevention of rethrombosis in essential thrombocythemia

Clinical and Applied Thrombosis/Hemostasis

Volumn 5, Issue 2, 1999, Pages 131-135

  Randi, Maria Luigia ^a,b   Rossi, Carla ^a   Fabris, Fabrizio ^a   Menapace, Laura ^a   Girolami, Antonio ^a  

^a UNIVERSITY OF PADUA MEDICAL SCHOOL   (Italy)

^b Instituto di Semeiotica Medica   (Italy)

Author keywords

Aspirin; Essential thrombocythemia; Myelotoxic drugs; Thrombo hemorrhagic complications

Indexed keywords

ACETYLSALICYLIC ACID; HYDROXYUREA; IMMUNOSUPPRESSIVE AGENT;

ADULT; AGED; ARTICLE; CANCER RISK; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REMISSION; THROMBOCYTHEMIA; THROMBOSIS; TREATMENT OUTCOME;

EID: 0032918938     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/107602969900500210     Document Type: Article

References (23)

1. Schafer AI. Essential thrombocythemia. In: Coller BS, ed. Progress in hemostasis and thrombosis. Philadelphia: WB Saunders, 1991;10:69.
2. Randi ML. Stocco F, Rossi C, et al. Thrombosis and hemorrhage in thrombocytosis: evaluation of a large cohort of patients (357 cases). J Med 1991;22:213.
3. Van Genderen PJJ, Michiels JJ. Primary thrombocythemia: diagnosis, clinical manifestations and management. Ann Hematol 1993;67:57.
4. Weinfeld A, Swolin B, Westin J. Acute leukemia after hydroxyurea therapy in polycythemia vera and allied disorders: prospective study of leukaemogenicity with therapeutic implications. Eur J Hematol 1994;52:134.
5. Tartaglia AP, Goldberg JD, Berk PD, Wasserman LR. Adverse effect of antiaggregating platelet therapy in the treatment of polycythemia vera. Semin Hematol 1986;23:172.
6. Ruggeri M, Castaman G, Rodeghiero F. Is ticlopidine a safe alternative to aspirin for management of myeloproliferative disorders? Haematologica 1993;78:18.
7. Kutti J. The management of thrombocytosis. Eur J Hematol 1990; 44:81.
8. Murphy S, Iland H, Rosenthal D, Laszlo J. Essential thrombocythemia: an interim report from the polycythemia vera study group. Semin Hematol 1986;23:177.
9. Randi ML, Fabris F, Varotto L. et al. The effect of different doses of 32P in the treatment of primary thrombocytosis. Folia Hematol 1985;112:950.
10. Hirsh J, Dalen JE, Fuster V, et al. Aspirin and other platelet-active drugs. The relationship among dose, effectiveness and side effects. Chest 1995;108:2475.
11. The RISC group: Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 1990;336:827.
12. The Dutch TIA trial study group. A comparison of two doses of aspirin (30 mg vs 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N Engl J Med 1991;325: 1261.
13. Farrel B, Godwin J, Richards S, et al. The United Kingdom transient ischemic attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry 1991;54:1044.
14. Antiplatelet Trialist Collaboration. Collaborative overview of randomised trials of anti-platelet therapy I: prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994;308:81.
15. Schafer AI. Management of essential thrombocythemia. Curr Opin Hematol 1996;3:341.
16. Cortellazzo S, Finazzi G, Ruggeri M, et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med 1995;332:1132.
17. Rocca B, Ciabattoni G, Tartaglione R, et al. Increased thromboxane biosynthesis in essential thrombocythemia. Thromb Haemost 1995;74:1225.
18. Shafer AI. Bleeding and thrombosis in myeloproliferative disorders. Blood 1984;64:1.
19. Watson KV, Key N. Vascular complications of essential thrombocythemia: a link to cardiovascular risk factors. Br J Haematol 1993;83:198.
20. Randi ML, Fabris F, Cella G, et al. Cerebral vascular accidents in young patients with essential thrombocythemia: relation with other known cardiovascular risk factors. Angiology 1998;49:477.
21. Cortellazzo S, Viero P, Finazzi G, et al. Incidence and risk factors for thrombotic complications in an historical cohort of 100 patients with essential thrombocythemia. J Clin Oncol 1990;8:556.
22. Bellucci S, Janvier M, Tobelem G, et al. Essential thrombocythemia: clinical, evolutionary and biological data. Cancer 1986;58: 2440.
23. Van Genderen PJJ, Mulder GH, Waleboer M, et al. Prevention and treatment of thrombotic complications in essential thrombocythemia: efficacy and safety of aspirin. Br J Haematol 1997;97:179.